Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations

Tuesday, February 13, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has promoted Naresh Tanna to Vice President of Investor Relations. This new senior-level position aims to enhance and expand the company's existing strategic investor relations program. The move reflects the company's commitment to strengthening its engagement with investors and stakeholders.
Price reaction · baseline $11.253 (2024-02-12 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close
-0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Promotion of Naresh Tanna indicates growth in leadership.
  • Strengthening of investor relations is a strategic move.
  • Focus on enhancing existing IR program shows commitment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

– Dedicated Senior-Level Function will Enhance and Expand Existing Strategic IR Program DURHAM, N.C. –(BUSINESS WIRE)–Feb. 13, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing

Frequently Asked Questions

Who was promoted at Precision BioSciences?

Naresh Tanna was promoted to Vice President of Investor Relations.

What is the purpose of Naresh Tanna's promotion?

The promotion aims to enhance and expand the existing strategic IR program.

What company is Naresh Tanna associated with?

Naresh Tanna is associated with Precision BioSciences, Inc.

What does Precision BioSciences focus on?

The company focuses on advanced gene editing using its ARCUS platform.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences Naresh Tanna investor relations gene editing
Last updated: Feb 13, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →